THY1 and inflammatory bowel disease: ILC depletion strategies, using anti-Thy1 or anti-CD90 monoclonal antibodies, have been successful in two different experimental models of IBD, Helicobacter hepaticus-induced intestinal inflammation and T-bet−/−Rag2−/− (TRUC) mice that develop spontaneous colitis, respectively [16, 39].